<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00781716</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.0-Sep 10, 2008</org_study_id>
    <nct_id>NCT00781716</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction (STEMI) and Analysis of Current Status of Emergency PCI Green Channel for STEMI Patients in China</brief_title>
  <acronym>CREST-MI</acronym>
  <official_title>Comparison of Safety and Efficacy of CYPHER® Sirolimus Stent and ENDEAVOR® Zotarolimus Stent in Patients With Acute ST Elevation Myocardial Infarction and Analysis of Current Status of Emergency PCI Green Channel for Patients With ST Elevation Myocardial Infarction in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to compare the clinical effect of CYPHER® stent and ENDEAVOR® stent in patients&#xD;
      with acute ST elevation myocardial infarction. It also aims to analyze the current status of&#xD;
      emergency PCI green channel (time taken from door→ hospital→ PIC sign-off→ needle→ balloon)&#xD;
      for patients with ST elevation myocardial infarction in China.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">May 2011</completion_date>
  <primary_completion_date type="Anticipated">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac Events defined as death, MI (Q wave and non-Q wave), emergent cardiac bypass surgery, or target lesion revascularization (repeat PTCA or CABG)</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1020</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cypher Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cypher Sirolimus-Eluting Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endeavor Stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endeavor Zotarolimus-Eluting Coronary Stent System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Drug eluting coronary stent system</intervention_name>
    <description>Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System</description>
    <arm_group_label>Cypher Stent</arm_group_label>
    <arm_group_label>Endeavor Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be ≥18 years and ≤75 of age.&#xD;
&#xD;
          2. Prolonged, continuous (≥ 30 min) chest pain despite nitrate and: (1) ST-segment&#xD;
             elevation ≥ at least 2 leads, with reciprocal ST-segment elevation ≥ 0.05mv and&#xD;
             precordial leads ST-segment elevation ≥ 0.01mv, or (2) newly developed left bundle&#xD;
             branch block&#xD;
&#xD;
          3. Symptoms ≥ 30 min and ≤12 hours&#xD;
&#xD;
          4. The patient has consented to participate and has authorized the collection and release&#xD;
             of his medical information by signing the &quot;Patient Informed Consent Form&quot;&#xD;
&#xD;
          5. All lesions requiring interventions in one or more native coronary arteries are&#xD;
             amendable for implantation of one or more Cypher® Sirolimus-Eluting Coronary Stent&#xD;
             System or Endeavor® Zotarolimus-Eluting Coronary Stent&#xD;
&#xD;
          6. The patient or guardian is willing and able to cooperate with study procedures and&#xD;
             required follow up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant and breast-feeding female and female of childbearing potential, who possibly&#xD;
             plan to become pregnant any time after enrollment into this study.&#xD;
&#xD;
          2. Systemic (intravenous) Sirolimus use within 12 months.&#xD;
&#xD;
          3. Patients with hypersensitivity or allergies to one of the drugs or components&#xD;
             indicated in the Instructions for Use of either stents.&#xD;
&#xD;
          4. History of bleeding diathesis or known coagulopathy (including heparin-induced&#xD;
             thrombocytopenia), or will refuse blood transfusions.&#xD;
&#xD;
          5. Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery&#xD;
             within 2 months.&#xD;
&#xD;
          6. Current platelet count &lt;100 x 10^9cells/L or Hgb &lt;10 g/dL.&#xD;
&#xD;
          7. Fibrinolytic therapy for current MI treatment&#xD;
&#xD;
          8. Previous coronary intervention on target vessel or post-CABG vessel disease&#xD;
&#xD;
          9. Transplant patients&#xD;
&#xD;
         10. Patients with EF&lt;25%&#xD;
&#xD;
         11. Patients with cardiogenic shock; with a life expectancy shorter than 12 months&#xD;
&#xD;
         12. Severe kidney dysfunction: Creatinine level ≥2.0mg/dL or dependence on dialysis.&#xD;
&#xD;
         13. Severe hepatic dysfunction (AST and ALT ≥ 3 times upper normal reference values).&#xD;
&#xD;
         14. The patient is currently, and during the CREST-MI Study, participating in another&#xD;
             investigational device or drug study that clinically interferes with the CREST-MI&#xD;
             study endpoints; or requires coronary angiography or other coronary artery imaging&#xD;
             procedures. The patient may only be enrolled in the CREST-MI Study once.&#xD;
&#xD;
         15. Severe tortuous or calcified vessel; stent can not or has difficulty to go through;&#xD;
             blood vessel diameter is smaller than the minimum stent diameter available; patients&#xD;
             unsuitable for stent implantation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LeFeng Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LeFeng Wang, MD</last_name>
    <phone>86-13601255020</phone>
    <email>CrestMI@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caihong Wang</last_name>
    <phone>86-13001980897</phone>
    <email>crest_mi@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital Heart Center</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>10000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>LeFeng Wang, MD</last_name>
      <phone>86-13601255020</phone>
      <email>CrestMI@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 28, 2008</study_first_submitted>
  <study_first_submitted_qc>October 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2008</study_first_posted>
  <last_update_submitted>October 28, 2008</last_update_submitted>
  <last_update_submitted_qc>October 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. LeFeng Wang/Director of the Cath Lab</name_title>
    <organization>Beijing Chao Yang Hospital Heart Center</organization>
  </responsible_party>
  <keyword>ST elevation myocardial infarction</keyword>
  <keyword>Drug eluting stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

